In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was $8.62 for the day, down -0.12% from the previous closing price of $8.63. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 1.32 million shares were traded. AUPH stock price reached its highest trading level at $8.89 during the session, while it also had its lowest trading level at $8.55.
Ratios:
Our analysis of AUPH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.46. For the most recent quarter (mrq), Quick Ratio is recorded 5.26 and its Current Ratio is at 5.93. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.18.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 07 ’25 when Keenan Greg sold 8,305 shares for $8.23 per share. The transaction valued at 68,350 led to the insider holds 153,484 shares of the business.
Greenleaf Peter sold 195,593 shares of AUPH for $1,564,744 on Mar 03 ’25. The Chief Executive Officer now owns 1,953,892 shares after completing the transaction at $8.00 per share. On Mar 04 ’25, another insider, Greenleaf Peter, who serves as the Chief Executive Officer of the company, sold 164,947 shares for $7.92 each. As a result, the insider received 1,306,380 and left with 1,788,945 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1164596480 and an Enterprise Value of 909657408. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 31.21, and their Forward P/E ratio for the next fiscal year is 11.37. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.71 while its Price-to-Book (P/B) ratio in mrq is 3.39. Its current Enterprise Value per Revenue stands at 3.678 whereas that against EBITDA is 14.69.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.23, which has changed by 0.58931863 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $10.67, while it has fallen to a 52-week low of $5.20. The 50-Day Moving Average of the stock is 5.48%, while the 200-Day Moving Average is calculated to be 6.28%.
Shares Statistics:
AUPH traded an average of 1.50M shares per day over the past three months and 2166650 shares per day over the past ten days. A total of 137.75M shares are outstanding, with a floating share count of 119.37M. Insiders hold about 11.64% of the company’s shares, while institutions hold 45.05% stake in the company. Shares short for AUPH as of 1749772800 were 10530635 with a Short Ratio of 6.69, compared to 1747267200 on 10877775. Therefore, it implies a Short% of Shares Outstanding of 10530635 and a Short% of Float of 8.520000399999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
